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Abstract
Introduction: We present our work of monitoring 202 different patients with markedly elevated serum index for lipemia whereby serum 
samples were clear. We tried to clarify the cause of occurrence of these indices which were detected in the years 2006-2010 on Siemens Dimension 
analyzers.
Materials and methods: In samples with unusual lipemia index we measured the concentration of lipids (total cholesterol, triglycerides, 
HDL and LDL cholesterol, Lp(a), ApoA1, ApoB), total proteins and checked for possible interferents (rheumatoid factor, immunoglobulins). We per-
formed serum protein and immuno- electrophoresis. We investigated the repeatability of unusual lipemia indices during the day and after different 
time periods and we compared them on four different analyzers (RXL Max, Vista, Hitachi 911 and former Olympus AU640).
Results: In 87% of 202 samples we found a monoclonal or biclonal peak in serum protein electrophoresis. Different types of paraproteins were 
confirmed with immunofixation electrophoresis. In the remaining 13%, polyclonal elevated concentrations of immunoglobulins were measured. 
Other parameters had no influence on appearing of these indices. The repeatability of indices was good during the first day of measurements (P va-
lues > 0.05) and markedly lower in the next days or after 3 and 12 months (P values < 0.05). The indices were elevated only on Dimension analyzers, 
but not on Hitachi and former Olympus analysers.
Conclusion: A markedly elevated lipemia index in a clear serum sample measured on Siemens analyzers Dimension indicates a high possibility 
for the presence of a paraprotein in the sample. 
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Spectral interferences (haemolysis, icterus, and 
lipemia) can significantly affect the measurements 
of different parameters in general chemistry . Due 
to the presence of high concentrations of haemo-
globin, bilirubin or lipids causing these interfer-
ences, the measured values may be altered (1-3) . 
Therefore, detecting spectral interferences and 
avoiding report of false results is very important in 
laboratories .
The most common way of detecting spectral in-
terferences is a visual assessment of a serum sam-
ple (4) . Samples with interference are identifiable 
through a characteristic color or turbidity . In he-
molysis the sample colors light or intense red, in 
icterus the colors range from dark yellow to light 
brown or even green . Lipemic serums are usually 
turbid and white (milky) . 
The other option for detecting spectral interfer-
ences is an automated measurement of serum in-
dex which can be performed on most biochemical 
analyzers (4-6) . Such measurements are almost ur-
gent in laboratories with a large number of sam-
ples or laboratories using preanalytical lines where 
samples are not available for visual assessment of 
interferences before measurements . 
The paper discusses a special feature of serum in-
dex measurements observed during our work 
with Siemens Dimension analyzers (Siemens 
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(Roche Diagnostics GmbH, Mannheim, Germany) 
and former Olympus 640 (former Olympus Diag-
nostica GmbH, Lismeehan, Ireland; Beckman Coul-
ter) .
We present the methods of detection of unusual 
high lipemia indices and their characteristics as 
well as the results of investigations of other pa-
rameters with which we wanted to clarify their 
possible impact on the emergence of these indi-
ces .
Materials and methods
Measurements of serum index
HIL (haemolysis, icterus, lipemia) represents the 
measurement of serum index on all Dimension an-
alyzers - RXL, RXL Max, Xpand, Xpand Plus, and 
Vista (13) . The HIL abbreviation represents a three 
digit number . The first number shows the estimat-
ed effect of haemolysis, the second the effect of 
icterus, and the third the effect of lipemic sample 
on biochemical measurements (Example HIL 123: 
1 is assessment of haemolysis, 2 for icterus, 3 for 
lipemia) . Dimension Vista analyzer is an exception . 
The measuring principle is the same as on other 
analyzers, however, the assessments of all three in-
terferences are expressed as individual figures . In-
terference value is expressed in numbers from 1 to 
8 on Dimension Vista analyzer and from 1 to 6 on 
other Dimension analyzers . The interference effect 
on biochemical measurements increases with as-
cending numbers: number 1 indicates a usual 
sample without interferences (HIL 111: no haemol-
ysis in sample, no icterus, no lipemia), the number 
6 or 8 indicates the highest possible interference 
in a sample (e .g .: HIL 666 – strong haemolysis in 
sample, sample highly icteric and lipemic) . 
Serum index measurements are performed simul-
taneously with routine measurements of other ex-
aminations on a sample . The analyzer dilutes a 
small volume of sample (RXL Max 20 µL, Vista 10 
µL) with water and measures absorbance at indi-
vidual wavelengths defined for each spectral in-
terference (Table 1) . The measured absorbencies 
are converted by means of mathematical formulas 
into concentrations of haemoglobin, bilirubin or 
HealthCare Diagnostics, Newark, DE, USA), i .e . high 
serum indices for lipemia in samples visually clear 
and transparent, showing no typical characteris-
tics of lipemic samples . High serum indices for 
lipemia are unusual in such samples and probably 
result from the presence of some other disturbing 
substance and not from increased concentrations 
of lipids . 
The Siemens Healthcare Diagnostics company, as 
the manufacturer of Dimension analyzers, does 
not have enough data yet to explain this phenom-
enon . Different sources from literature do not re-
port of such cases either . The only exception is an 
article by the English authors Monk et al . entitled 
“A monoclonal protein identified by an anomalous 
lipaemia index”, published in 2009 (7) . The article 
reports about a case with a high lipemic serum in-
dex identified in a sample during routine measure-
ments on Beckman Coulter DxC800 analyzer 
(Beckman Coulter UK Ltd, High Wycombe, UK), 
whereby the serum did not have the lipemic sam-
ple appearance . With further examinations they 
confirmed a monoclonal IgM kappa paraprotein in 
the sample and the non-Hodgkin B-cell lympho-
ma in the patient . Other articles on monoclonal 
immunoglobulins (paraproteins) report of the lat-
ter as interferents in performing measurements of 
individual biochemical tests; however, they do not 
provide information regarding the effect on serum 
index measurements (8-12) . 
In this article we present our research on clarifica-
tion of unusual lipemia indices on Dimension RXL 
Max and Dimension Vista analyzers which was 
performed in the years 2006-2010 . We tried to de-
termine the cause of appearance of these indices, 
in which patients and how often they occur, i .e . 
whether these indices occur occasionally or are 
present in specific diseases . We also tried to deter-
mine if unusual lipemia indices occur also on other 
biochemical analyzers . 
We therefore examined the potential impact of li-
pids, as well as various interferents in general 
chemistry, like the rheumatoid factor and immu-
noglobulins . We compared samples with unusual 
lipemia index on four different analyzers – beside 
Dimension RXL Max and Vista also on Hitachi 910 
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triglycerides and these are further categorized 
with numbers from 1 to 6 or 8 marking the pres-
ence of interference (Table 2) . The decision wheth-
er interference has a significant impact on the 
measured results of biochemical examinations is 
made by comparing the measured serum index 
with the set, i .e . critical values, defined on the basis 
of validation by Siemens company . When the 
measured serum index in a sample is the same or 
higher than the defined critical index value, the 
measured results are impacted by the interferenc-
es . 
The method of measuring serum indices on differ-
ent biochemical analyzers differs to a certain ex-
tent . Different equipment manufacturers have val-
idated somewhat different systems of index meas-
uring, although the principle is similar; the serum 
sample is diluted with water or water diluent, ab-
sorbance of haemoglobin, bilirubin and lipids is 
measured at different wavelengths, and different 
mathematical conversions of the measured ab-
sorbance into concentrations are used (6,14) . The 
display of the measured serum index also varies 
on different analysers (e .g . HIL factors from 1-6 or 
8 / Siemens; categories “N, 1+ to 5+” / former 
Olympus AU 640; numerical value in units of icter-
us, haemolysis and lipemia / Roche Hitachi 911) . 
Sample and test selection
We performed routine biochemical measurements 
on Siemens Dimension RXL Max analyzers (former 
Dade Behring) from September 2006 until June 
2010, and on Dimension Vista analyzers from June 
2010 on .
Samples, which were routinely tested on our bio-
chemical analyzers and for which a warning was 
issued in LIS for potential impact of lipemia on the 
results, were checked and visual assessment was 
provided . From September 2006 until December 
2010 we thus discovered 202 different patients 
with extremely high lipemic index whereby the 
serum samples were clear or without signs of 








Haemolysis 405/700 570/600 + 660/700 410/480 + 600/800
Icterus 452/700 480/505 + 570/600 480/570 + 600/800
Lipemia 700 660/700 660/800
1Siemens Dimension analysers – RXL, RXL Max, Xpand, Xpand Plus, Vista; 2BC – Beckman Coulter with former Olympus analysers .
Table 2. Concentrations of haemoglobin, bilirubin and triglycerides with appropriate serum indices for RXL Max and Vista analysers, 









RXL VISTA RXL VISTA RXL VISTA
1 H≤0 .25 H≤0 .10 I≤34 .2 I≤34 .2 L≤0 .28 L≤0 .56
2 0 .25<H≤0 .50 0 .10<H≤0 .25 34 .2<I≤85 .5 34 .2<I≤85 .5 0 .28<L≤0 .57 0 .56<L≤1 .13
3 0 .50<H≤2 .00 0 .25<H 0 .50 85 .5<I≤342 85 .5<I≤171 0 .57<L≤2 .26 1 .13<L≤2 .26
4 2 .00<H≤3 .00 0 .50<H≤2 .00 342<I≤684 171<I≤256 2 .26<L≤6 .78 2 .26<L≤4 .52
5 3 .00<H≤5 .00 2 .00<H≤3 .00 684<I≤1026 256<I≤342 6 .78<L≤11 .3 4 .52<L≤6 .78
6 5 .00<H≤10 .0 3 .00<H≤5 .00 1026<I≤1368 342<I≤684 11 .3<L≤33 .9 6 .78<L≤9 .04
7 5 .00<H≤10 .0 684<I≤1026 9 .04<L≤11 .3
8 H>10 .0 I>1026 L>11 .3
1Triglyceride concentration was simulated with IntralipidTM supplementation .
Fliser E . et al . Serum index and paraproteins
Biochemia Medica 2012;22(3):352-62 
  355
Table 3. Parameters that were measured to evaluate their impact on the occurrence of high serum indices in clear serum samples; 
methods, measuring ranges, instruments and reagent manufacturers .
Analyte Instrument Method Measuring range Manufacturer
IgG Siemens BN II nephelometer Nephelometric method






IgA Siemens BN II nephelometer
Siemens BN II 
nephelometer
Nephelometric method
Siemens BN II 
nephelometer
Nephelometric method








Siemens BN II 
nephelometer
IgM
Siemens BN II 
nephelometer
Nephelometric method








Siemens BN II 
nephelometer









Siemens BN II 
nephelometer Nephelometric method














Interlab Microtech 648 PC
Serum protein 
electrophoresis
/ 3 Interlab Scientific 
Instruments, Roma, Italy
Monoclonal 
immunoglobulin Sebia Hydrasis Immuno-electrophoresis / 




Siemens Dimension RXL 
Max, Vista
Cholesterol esterase 1 .30–15 .50 mmol/L2
Siemens HealthCare 
Diagnostics, Newark, DE, 
USA
Triglycerides Siemens Dimension RXL Max, Vista GPO-PAP Enzymatic 0 .02–11 .30 mmol/L
2
Siemens HealthCare 
Diagnostics, Newark, DE, 
USA




0 .05–3 .89 mmol/L2
Siemens HealthCare 
Diagnostics, Newark, DE, 
USA
LDL cholesterol Siemens Dimension RXL Max, Vista
Direct (enzymatic 
colorimetric) method 0 .00–7 .80 mmol/L
2
Siemens HealthCare 
Diagnostics, Newark, DE, 
USA
Total protein (TP) Siemens Dimension RXL Max, Vista




Diagnostics, Newark, DE, 
USA
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lipemia . The majority of 202 patients were treated 
at the Department for Haematology (96), Depart-
ment for Gastroenterology (31), Emergency Unit 
(27), Department for Rheumatology (16), Depart-
ment for Infectious diseases (9), and elsewhere 
(23) .
As these patients received either outpatient treat-
ment due to first aid or control check-ups, or were 
hospitalized at different departments, we re-
ceived for each of these patients a different num-
ber of samples – either one single sample, a se-
ries of samples at check-ups, or even a series of 
everyday samples consecutively in hospitalized 
patients . 
We considered all indices for lipemia, which were 
equal to or higher than 4 as unusual high lipemia 
index (in a clear serum sample); values 4, 5 or 6 
on RXL Max analyzer and values from 4 to 8 on 
the Vista analyzer . Index 4 is defined as the mini-
mum concentration of 2 .26 mmol/L of triglycer-
ides on both instruments . We set index 4 as a 
threshold value because at this stage we did not 
expect any clear or only slightly cloudy samples 
any more .
The samples were processed according to the fol-
lowing algorithm: 
In 202 different samples (of all patients with unu-
sual serum index for lipemia), regardless of the de-
partment they were treated at, we performed si-
multaneously additional examinations . Regarding 
the increased serum index for lipemia, we meas-
ured lipid concentration in samples (total choles-
terol, triglycerides, HDL, LDL, Lp(a), ApoA1, ApoB) 
and examined their potential impact on appear-
ing of unusual lipemia indices by comparison with 
a control group of 50 samples . The control group 
was constituted of 50 randomly selected samples 
with established monoclonal peak in serum pro-
tein electrophoresis and with a normal serum in-
dex HIL 111 . In the selected 202 different samples 
of patients with unusual serum index for lipemia 
we checked also for other possible interferences – 
concentration of rheumatoid factor (RF), immuno-
globulins (IgG, IgA, IgM, kappa and lambda light 
chains), and the concentration of total proteins . 
We performed serum protein electrophoresis and 
immunoelectrophoresis . When the sample vol-
ume was insufficient for the mentioned examina-
Analyte Instrument Method Measuring range Manufacturer








Siemens BN ProSpec 






Cryoglobulins PU 8675 VIS Spectrophotometer Lowry method 0–400 mg/L
Philips, Cambridge,
United Kingdom




Serum index Hitachi 911 LIH / Roche Diagnostics GmbH, Mannheim, Germany
Serum index Siemens Dimension RXL Max, Vista HIL /
Siemens HealthCare 
Diagnostics, Newark, DE, 
USA
1A change of lower and upper range value is possible with dilution of the sample . 2A change of upper range value is possible 
with dilution of the sample . 3Detection limit for monoclonal immunoglobulin is 1 .0 g/L . 4Detection limit for monoclonal 
immunoglobulin is between 0 .12-0 .25 g/L . 5Name regarding the time of measurements; otherwise Beckman Coulter .
Table 3. (continued)
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tions, we requested for an additional blood sam-
ple . Examinations on this sample were performed 
only if additional blood was taken within 2 hours 
and the serum index in the sample was the same . 
We determined the repeatability of indices by 
measuring serum index in 40 samples of different 
patients 5 times on the first day after the sample 
arrived to the laboratory . All measurements were 
done on Dimension RXL Max analyzer . Samples 
were selected at random, but only from those pa-
tients, where unusual high lipemia index already 
appeared and where we included a preliminary 
sample of the patient to additional examinations 
in the first paragraph . 
Day-to-day and long-term repeatability were de-
termined by measurements of serum index in 98 
samples of different patients on the first day after 
the sample arrived to the laboratory and after a 
certain period of time: (1) 1 sample aliquot was 
stored at 2-8 °C and serum index measured 5 days 
consecutively . (2) 1 sample aliquot was stored at 
-20 °C and serum index measured after 3 months . 
(3) 1 sample aliquot was stored at -20 °C and se-
rum index measured after 12 months . All measure-
ments were done on Dimension RXL Max analyzer . 
Like before, samples were selected at random, but 
only from those patients, where unusual high 
lipemia index already appeared and where we in-
cluded a preliminary sample of the patient to ad-
ditional examinations in the first paragraph .
We compared lipemia indices on different analyz-
ers by measuring 42 samples of different patients 
on RXL Max, Vista, Hitachi 911 and former Olym-
pus AU640 analyzers . Measurements were per-
formed within 4 hours after the sample arrived to 
the laboratory . Again, samples were selected at 
random, but only from those patients, where unu-
sual high lipemia index already appeared and 
where we included a preliminary sample of the 
patient to additional examinations in the first par-
agraph .
During a 3-month period from February to April 
2008 we daily checked all samples where we per-
formed serum protein electrophoresis . In 79 sam-
ples with established monoclonal peak we 
checked or measured the lipemia index on the 
same day of sample arrival to the laboratory on Di-
mension RXL Max analyzer .
By data research of preliminary test reports we 
tried to find eventually routinely measured con-
centrations of cryoglobulins in patients with unu-
sual lipemic serum index . We have not performed 
these measurements simultaneously as an addi-
tional test (like other tests in paragraph 1) because 
the blood sample for analysis needs to be (as a re-
sult of cryoglobulin precipitation) transferred to 
the laboratory immediately at 37 °C .
By analyzing the data, we also attempted to deter-
mine the incidence of unusual high serum indices 
for lipemia and tried to acquire the respective di-
agnoses of patients .
Serum samples were used for all analyses . Samples 
were drawn into BD Vacutainer® SSTTM II Advance 
tubes (Becton Dickinson, Plymouth, United King-
dom), and centrifugated 10 minutes at 1990 x g . 
Cryoglobulin measurements were performed in 
BD Vacutainer® CAT tubes (Becton Dickinson, Plym-
outh, United Kingdom), brought to the laboratory 
immediately in warm water and centrifugated 10 
minutes at 1990 x g . All measurements were con-
ducted on the analyzers and methods listed in Ta-
ble 4 . 
Table 4. Number of patients with lipemia index from 4 to 6 (RXL Max) or from 4 to 8 (Vista) and a clear serum; sex and age of patients .
Variable Total RXL Max Vista P
Number of patients 202 109 93
Women 107 (53%) 56 (51%) 51 (55%)
Age (years) 70 (15-92) 70 (19-91) 70 (15-92)
Mean serum index for lipemia1 4 .3 ± 0 .8 4 .1 ± 0 .4 4 .6 ± 1 .0 < 0 .0012
1Serum indices are presented as mean values to one decimal place for a better illustration of the differences in measurements . 2P 
value for differences between mean values of serum indices on RXL Max and Vista analysers, Mann-Whitney Test .
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Statistical analysis
The Kolmogorov-Smirnov test was used to assess 
the normality of distribution of investigated pa-
rameters . Results were expressed as mean ± stand-
ard deviation for normal distribution and as medi-
an with interquartile range if the distribution was 
not normal (15) . Age was expressed as median 
(minimum-maximum age) . Differences were tested 
by two-tailed t-test for independent samples with 
normal distribution and by non-parametric tests 
for other data; Mann-Whitney U-test for independ-
ent samples which did not follow normal distribu-
tion, two-tailed Pearson chi-square test for nomi-
nal values, Friedman’s test and Wilcoxon signed 
rank test for repeatability of serum indices . The val-
ues P < 0 .05 were considered statistically signifi-
cant . Statistical analysis was done using IBM® SPSS® 
Statistics version 19 .0 (SPSS Inc ., New York, USA) .
Results 
In the years 2006-2010 we have discovered 202 dif-
ferent patients with markedly elevated serum 
lipemia index and a clear serum sample . 109 pa-
tients were measured on RXL Max analyzer with 
indices 4, 5 or 6 and the remaining 93 patients on 
Vista analyzer with indices from 4 to 8 (Table 4) . 
There were slightly more women than men (Table 
4) . 79% of all lipemia indices were in class 4 and 
14% in class 5 . The proportion of other lipemia in-
dices was very small (3% for lipemia index 6, 2% 
for index 7 and 2% for index 8) .
In 176 of 202 samples (87% of samples) we de-
tected a monoclonal or biclonal peak with serum 
protein electrophoresis; in the remaining 26 
samples (13%) we found polyclonal elevated 
concentrations of immunoglobulins (Table 5) . 
The most common types of paraproteins set by 
immunoelectrophoresis were IgM + kappa and 
IgG + kappa .
The median concentration of IgG in all samples 
with IgG paraprotein (IgG + kappa, IgG + lambda, 
IgG in biclonal peak) was 18 .8 (13 .6-32 .1) g/L, re-
gardless of the measured lipemia index ranging 
from 4 to 8 . The median IgM concentration in all 
samples with IgM paraprotein (IgM + kappa, IgM + 
lambda, IgM in biclonal peak) was 16 .45 (9 .70-
28 .58) g/L, regardless of the measured lipemia in-
dex in the range 4-8 .
Unusual high lipemia indices did not occur in all 
samples with a monoclonal or biclonal peak . From 
79 samples with the established paraprotein and a 
clear serum found during a 3-month period at our 
laboratory, only 20 (25%) had a lipemia index 4 or 
more .
Table 5. Total number of samples with individual (monoclonal, biclonal or polyclonal) immunoglobulins and median concentration 






4 5 6 4 5 6 7 8
IgM + kappa 67 14 .80 (9 .41-22 .83)2 33 7 - 20 4 3 - -
IgG + kappa 50 19 .0 (13 .7-32 .5)3 24 4 - 12 3 3 2 2
IgM + lambda 29 25 .00 (12 .30-32 .10)2 10 2 - 11 4 - 1 1
IgG + lambda 14 16 .1 (11 .5-23 .8)3 6 - 1 7 - - - -
polyclonal Ig1 26 26 .6 (18 .5-30 .5)4 13 - - 12 1 - - -
biclonal Ig1 15 20 .6 (16 .7-34 .3)
5
17 .60 (7 .68-22 .90)6 8 - - 3 3 - - 1
IgA + lambda 1 48 .917 1 - - - - - -
1Ig – immunoglobulins . 2Median and interquartile range for IgM immunoglobulin of the monoclonal peak . 3Median and 
interquartile range for IgG immunoglobulin of the monoclonal peak . 4Median and interquartile range for IgG immunoglobulin 
of the polyclonal peak . 5Median and interquartile range for IgG immunoglobulin of the biclonal peak . 6Median and interquartile 
range for IgM immunoglobulin of the biclonal peak . 7Concentration of the paraprotein .
Fliser E . et al . Serum index and paraproteins
Biochemia Medica 2012;22(3):352-62 
  359
We found no statistically significant differences in 
mean or median concentrations of other tested 
analytes between samples with unusual lipemia 
index and the control group (Table 6) .
Due to different classification of serum indices in 6 
or 8 concentration classes, the measured values on 
RXL Max and Vista analyzers were not entirely 
comparable (Figure 1) . Mean lipemia index in 42 
samples from different patients was 4 .1 on RXL 
Max and 4 .6 on Vista . All measured values on 
Olympus AU640 and Hitachi 911 were normal (“N” 
on Olympus) or very low (the highest value “21” or 
0 .24 mmol/L of triglycerides on Hitachi 911) . The 
measured values on both instruments fell into 
class 1 according to Siemens classification of se-
rum indices .
Five successive repetitions of serum index meas-
urements in 40 samples of different patients indi-
cated a good repeatability; no significant differ-
ences were found between indices with Fried-
man’s test (P = 0 .637) and with Wilcoxon signed 
rank test when compared to the first measure-
ment (P values > 0 .157) . 154 of 160 repetitions had 
the same lipemia index as the first measurement . 
Only 6 of 160 measurements (3 .75%) had a lower 
lipemia index by 1 class . 
Unusual high lipemia indices in 98 samples from 
different patients were not stable for long . We 
found significant differences with Friedman’s 
test (P < 0 .001) and with Wilcoxon signed rank 
test in comparing the measurements of each 
day, after 3 months, and after 12 months with 
the measurements on the first day . The lipemia 
indices gradually lowered from one day to the 
next in most of the samples . Mean lipemia in-
dex was 4 .2 on the first day of measurement 
and 3 .6, 3 .3, 2 .9, and 2 .5 in the days following . 
Mean value after 3 months was 2 .7 and 1 .9 after 
one year .
In 5-day measurements from specimens stored 
at 2-8 °C in a refrigerator the lipemia index nor-
malised (L = 1) in 5 samples already on the sec-
ond day of the measurements . After five days the 
same lipemia index retained only in 9 samples . 
In these 9 samples various types of monoclonal 
immunoglobulins were present (IgG + kappa, 
IgM + kappa, IgM + lambda, biclonal IgM + kapa, 
lambda) .
In measurements of frozen aliquots at -20 °C after 
3 and 12 months, only 14 samples had the same 
index after 3 months of storage as the first day of 
measurements and only 5 samples after 12 months 
of storage . In these 5 samples IgM + kappa or IgM 
+ lambda paraprotein was present .
By data research we found results of cryoglobu-
lin measurements in test reports of 12 out of 202 
patients with unusual high lipemia index . In 
these test reports the concentration of cryoglo-
bulins was reported to be above the reference 
value . Serum protein electrophoresis was also 
45
1























Figure 1. Measurements of lipemia index in 42 samples of different patients with unusual high lipemia index on RXL Max, Vista, Hita-
chi 911 and former Olympus AU640 analyzers .
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given in the same reports; in 3 out of 12 test re-
ports a monoclonal peak was identified . In the 
remaining 190 patients with unusual high 
lipemia indices cryoglobulin measurements were 
not reported .
At the time of our research (2006–2010), we meas-
ured about 1 .170,000 serum samples on RXL Max 
and Vista analyzers . Serum indices were meas-
ured in most of them, with the exception of neo-
natal and some pediatric samples . During this 
time we have discovered unusual high lipemia in-
dex in 1240 samples, which represented 0 .1% of 
all sample framework . These 1240 samples repre-
sent repeated blood samples from 202 discov-
ered patients with unusual high lipemia index in-
cluded in our study . The repeated blood samples 
were due to control check-ups or even series of 
everyday samples consecutively in hospitalized 
patients .
For 78 patients, we managed to obtain a reliable 
diagnosis . Unusual high lipemia indices were seen 
mostly in patients with multiple myeloma (24), 
Waldenström’s macroglobulinemia (11) and other 
lymphomas (8), leukemia (9), liver cirrhosis (9), can-
cer (7), MGUS (Monoclonal gammopathy of unde-
termined significance) (4), diabetes (4), and Sjögren 
syndrome (2) .
Discussion
Markedly elevated lipemia index is usually a con-
sequence of a highly lipemic or turbidic sample . 
Appearance of such index in a clear serum is unu-
sual, unless interference is present (7) .
In measurements of serum index on Siemens Di-
mension analyses we found high lipemia indices 
as a consequence of immunoglobulins present in 
the sample . In 87% of 202 samples we discovered 
a monoclonal or biclonal peak in serum protein 
electrophoresis . In the remaining 13% of samples 
policlonal elevated immunoglobulin concentra-
tions were present . Other parameters which we 
measured to view their impact on unusual high 
lipemia index had no influence on appearing of 
these signals .
According to our work (1) the single occurrence of 
unusual high lipemia index does not indicate a re-
liable presence of a paraprotein in the sample; 
such indices occurred in a small proportion also in 
samples without a monoclonal peak . (2) Unusual 
high lipemia index is not typical for all samples 
with a paraprotein; in our research it has appeared 
only in 25% of all samples with a monoclonal peak 
found at our laboratory . (3) The appearance of this 
index and its size are not related to the presence 






(N = 50) P
TP (g/L) 77 ± 14 76 ± 14 0 .6251
CHOL (mmol/L) 4 .10 ± 1 .25 4 .00 ± 1 .31 0 .6402
TG (mmol/L) 1 .20 (0 .88-1 .62) 1 .43 (1 .14-2 .14) 0 .5061
HDL (mmol/L) 1 .09 ± 0 .43 1 .09 ± 0 .37 0 .9902
LDL (mmol/L) 2 .40 ± 0 .90 2 .33 ± 0 .85 0 .6002
ApoA1 (g/L) 1 .32 ± 0 .53 1 .25 ± 0 .53 0 .3682
ApoB (g/L) 0 .86 (0 .58-1 .18) 0 .74 (0 .63-1 .21) 0 .4401
Lp(a) (g/L) <0 .02-2 .13 <0 .02-1 .84 0 .5403
RF (IU/mL) <10-7990 <10-903 0 .6883
TP - Total protein, CHOL – Total cholesterol, TG – Triglycerides, HDL – HDL cholesterol, LDL – LDL cholesterol, RF – Rheumatoid 
factor . 1Mann-Whitney U-test, 2 Two-tailed T-test, 3Two-tailed Pearson chi-square test (χ2) .
Table 6. Mean and median concentration values for individual tests that were performed to determine their impact on the phe-
nomenon of high serum indices for lipemia in clear serum samples; values for 202 samples with unusual high lipemia index in a clear 
serum and values for the control group .
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tion range; for samples with a monoclonal peak 
we have demonstrated various types of parapro-
teins with different concentrations . 
According to our work, any high lipemia index in a 
clear serum on Dimension instruments represents 
a great probability for paraprotein presence in the 
sample . In this respect, class 4 of the lipemia index, 
as a limit value at which we started verifying the 
presence of monoclonal peak, proved to be rea-
sonable for both instruments .
With our research we were not able to determine 
why we perceived unusual high lipemia indices 
in limited samples (with paraproteins) . As a reac-
tion of determining unusual high lipemia index a 
precipitation of immunoglobulins probably takes 
place, which causes enhanced turbidity of the 
sample (16) . Immunoglobulins, which are normal-
ly present in a serum sample, do not cause this 
reaction, as well as not all paraproteins . We pre-
sume major immunoglobulin complexes appear 
in samples with unusual high lipemia indices that 
may decompose or precipitate over time, there-
by causing an unusual lipemia index . This pre-
sumption is based, in addition to the already 
mentioned three findings, on the following: (1) 
Unusual high lipemia indices have not been sta-
ble for a long time . The size of the indices is de-
creasing with time . In some samples, the index 
fully normalized already after a few hours of stor-
age at 2-8 °C . Only in rare cases the indices re-
mained unaffected, either for a few days at a 
temperature of 2-8 °C or up to 1 year, frozen at-20 
°C . (2) In 12 patients with unusual high lipemia in-
dices we found results of cryoglobulin measure-
ments with data research . All results were above 
the reference value . Monoclonal peak was pre-
sent only in 3 out of 12 patients . Unfortunately, in 
the remaining 190 patients with unusual high 
lipemia indices cryoglobulin measurements were 
not reported .
Since we assume the presence of immune com-
plexes in clear samples with unusual high lipemia 
index, we agree with the assumptions of Monk et 
al . that increased lipemia indices are probably not 
caused by the paraprotein itself, but with the pre-
cipitation of cryoglobulins (or other immune-com-
plexes) under certain conditions (7) .
Likewise, we could not answer why we perceived 
unusual high lipemia indices only on certain bio-
chemical analyzers . We believe the normal lipae-
mia index on Roche Hitachi and former Olympus 
instruments in the same samples might be due 
to a diverse way of measuring serum indices . It is 
not clear yet what the decisive difference is . 
These instruments use different solutions for 
sample dilution (water on RXL Max and Vista in-
struments, 0 .9% NaCl on Roche Hitachi and for-
mer Olympus instruments, according to the Eng-
lish authors Monk et al . Tris-HCl buffer with pH = 
7 .6 on Beckman Coulter DxC800 instrument), dif-
ferent proportions of human serum sample and 
diluent, different wavelengths at which the in-
terferences are measured, and different mathe-
matical equations for transforming absorbencies 
into a concentration of interfering substances 
(6,13,14) . 
Despite a number of open questions that remain 
regarding the cause of the occurrence of unusual 
lipemia indices, an important conclusion is that 
they occur in a large proportion of haematological 
diseases, like multiple myeloma, lymphoma, leu-
kemia, and even MGUS . The information of a pos-
sible presence of a monoclonal gammopathy can 
be of high importance in undiagnosed patients .
Conclusions 
Markedly elevated lipemia index in a clear serum, 
measured on Siemens analyzers Dimension RXL 
Max and Dimension Vista, indicates a high proba-
bility of a paraprotein presence in the sample . The 
size of the index alone does not imply the type of 
the paraprotein or his concentration range . The in-
formation of an unusual high lipemia index can be 
important because it suggests the possibility of 
the presence of serious haematological disease .
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